MedPath

Study on Clinical Value of Vitamin D in Recurrent Spontaneous Abortion

Completed
Conditions
Recurrent Spontaneous Abortion
Vitamin D Deficiency
Interventions
Dietary Supplement: Binom Vitamin D drops
Registration Number
NCT06002035
Lead Sponsor
Jianmei Xia
Brief Summary

The observational study is to compare vitamin D deficiency and related indicators among different spontaneous abortions in describe female reproductive health.The main question aim to answer is: the possible pathogenesis of recurrent spontaneous abortion caused by vitamin D.

Participants, who visit the RSA specialty clinic, will provide medical history information, regularly exam based on the condition, following up on pregnancy status.Participants will be asked to supply vitamin D preparation and do moderate exercise outdoors, comparing the effect after treatment.

Detailed Description

Examinations include uterine artery resistance parameter S/D, some embryonic chromosomes tested voluntarily, plasma VD content and the level of anticardiolipin antibody.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
1421
Inclusion Criteria
  • Clinical diagnosis of patients without spontaneous abortion;
  • Clinical diagnosis of patients with a spontaneous abortion;
  • Clinical diagnosis of patients with recurrent pontaneous abortions;
Exclusion Criteria
  • Patients with chromosomal abnormalities in RSA couples, such as balanced translocation;
  • Patients who take VD preparations or related VD supplements within 3 months before treatment;
  • Patients with a combination of certain malignant tumors and severe mental illness.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
patients with a spontaneous abortion(SA1)Binom Vitamin D dropsThe patients with VD deficiency or insufficiency take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added.
patients with RSA (SA2 and above)Binom Vitamin D dropsThe patients with VD deficiency or insufficiency take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added.
patients without spontaneous abortion(SA0)Binom Vitamin D dropsThe patients with VD deficiency or insufficiency take 30 drops (relative to 1ml) once a day, directly into the mouth or with complementary foods added.
Primary Outcome Measures
NameTimeMethod
Rate of the effect of vitamin D supplementation on adverse pregnancy outcomes2average of half of a year

Through outpatient follow-up, follow-up and inpatient information, pregnancy outcomes are classified according to Williams obstetrics, such as biochemical pregnancy which refers to the phenomenon where the sperm and egg combine but fail to return to the uterus for implantation, leading to miscarriage along with menstruation.

Rate of the effect of vitamin D supplementation on adverse pregnancy outcomes3average of half of a year

Through outpatient follow-up, follow-up and inpatient information, pregnancy outcomes are classified according to Williams obstetrics, such as loss of fetal heart rate which refers to the cessation of fetal heartbeat during pregnancy leading to miscarriage.

Rate of the effect of vitamin D supplementation on adverse pregnancy outcomes1average of 1 year

Through outpatient follow-up, follow-up and inpatient information, pregnancy outcomes are classified according to Williams obstetrics, such as empty sac which refers to the absence of a fetal sac or embryo bud (the amniotic sac is empty).

Rate of the effect of vitamin D supplementation on adverse pregnancy outcomes4average of half of a year

Through outpatient follow-up, follow-up and inpatient information, pregnancy outcomes are classified according to Williams obstetrics, such as spontaneous miscarriage in large months (greater than 12 weeks but less than 28 weeks) which refers to the cause of fetal death in the uterus, vaginal bleeding or flowing and abdominal pain leading to miscarriage.

Rate of the effect of vitamin D supplementation on adverse pregnancy outcomes5average of half of a year

Through outpatient follow-up, follow-up and inpatient information, pregnancy outcomes are classified according to Williams obstetrics, such as failure of fetal heart rate which the inability of the fetus to detect heartbeat leading to miscarriage.

Secondary Outcome Measures
NameTimeMethod
The difference of age in different number of spontaneous abortionsone day

Record patients' age through initial visit.

The change of plasma VD content in spontaneous abortions before and after supplying vitamin Daverage of 1 year

VD content was detected by liquid chromatography-tandem mass spectrometry using DISIGNS reagent. Dynamically monitor plasma VD at least twice every two months before and after treatment, and monitor early, mid, and late pregnancy each once after conception.

The difference of BMI in different number of spontaneous abortionone day

Record patients' height and weight through initial visit, and then calculate according to BMI formula.

The difference of uterine artery resistance parameter S/D in different number of spontaneous abortionsdynamic monitoring, average of half of a year

Use a three-dimensional ultrasound diagnostic instrument(GEVoluson-E10 or E8, USA) with a frequency of 5-9 MHz intracavity probe (non pregnancy) or 3-7 MHz abdominal probe (pregnancy) to examine bilateral S/D. Unpregnant patients were in mid luteal phase(5-7 days after ovulation), while pregnant patients were at 10 weeks of pregnancy.

The abnormality of some embryonic chromosomes tested voluntarily in spontaneous abortionsa month

use SNP gene chips to detect the embryonic chromosomes in spontaneous abortion; extract the genomic DNA of aborted embryo tissue, perform whole genome chromosome detection and determine whether the corresponding fragment or site is abnormal.

The change of the level of plasma anticardiolipin antibody in spontaneous abortions before and after supplying vitamin Daverage of 1 year

ACA level was detected by enzyme-linked immunosorbent assay using EUROIMMUN reagent. dynamically monitor plasma anticardiolipin antibody at least twice every two months before and after treatment, and monitor early, mid, and late pregnancy each once after conception.

Trial Locations

Locations (1)

Jianmei Xia

🇨🇳

Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath